• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Two Sticking Points With Johnson & Johnson: Guidance and Litigation Expense

While the ongoing litigation could be seen as a deterrent to investment, I think the more interesting story is its upcoming AFib detection study with Apple.
By STEPHEN GUILFOYLE
Jan 22, 2019 | 11:07 AM EST
Stocks quotes in this article: JNJ, AAPL

What do I think of when I think of Johnson & Johnson (JNJ) ? Basically, initial thoughts move to a stable firm that offers broad exposure for investors to both the pharmaceutical space, as well as the consumer products space, not to mention the attractive dividend. I always look for that. On Tuesday morning the firm reported to the street their fourth quarter results. On an adjusted basis, "Johnny John" as human traders often refer to this name, beat expectations for both EPS and revenues. The firm grew revenue slightly year over year despite a fairly nasty 4.7% negative impact based on currency valuations.

Pharmaceutical sales led all business lines, with 12.4% growth globally, though sales across all business lines performed at least fairly well internationally. There were two sticking points that made the market difficult for JNJ shareholders in early trade.

One... Guidance. The firm guided full year 2019 revenue toward a range of $80.4 billion to $81.2 billion, and non-GAAP EPS toward something in between $8.50 to $8.65. These projections were less that the industry had hoped for. Consensus view had been for EPS at the higher end of that range on revenue of more than $82 billion.

Two... Litigation Expense. The number just jumps right at the reader off of the balance sheet. For the fourth quarter, this line item cost the firm $1.288 billion, up from $645 million for Q4 2017. The horrific Q4 total forced that line for the past 12 months all the way up to $1.991 billion. Why? Several lawsuits have been brought that the firm's talcum powder contains asbestos. To be fair, the firm claims that the powder is asbestos free, and safe to use.

My Thoughts

While the ongoing litigation could be seen as a deterrent to investment, and it certainly slows my enthusiasm, I think the more interesting news story regarding JNJ actually broke last week ahead of earnings. What I refer to is the study that Johnson & Johnson will enter into later this year in cooperation with Apple (AAPL) . Where this goes is the use of an Apple Watch (Series 4) to detect Atrial fibrillation (AFib). Symptomatic of AFib is an irregular heartbeat that can result in stroke. Accelerating diagnosis could save lives. An estimated 33 million patients globally suffer from this condition.

Just FYI... this is in addition to an ongoing collaborative study launched in late 2017 between Apple and Stanford University School of Medicine, also centered around collecting data on irregular heart beats. Is this turning into an Apple article? I did take down about half of my Apple long last week, but this is interesting stuff, and may be where the real future of Apple's service-based revenue is derived from. Music? iCloud? Apple TV? I don't know. How does staying alive sound?

Trade Ideas (minimal lots)

Maybe if you're like me, you think that Apple AAPL is cheap, but perhaps sans a positive resolution on trade with China, not ready to pop. If you also think that JNJ is relatively cheap, as both of these names trade at forward looking PE ratios well below not only the broader marketplace, but their individual industry grouping as well, on top of nice dividends... maybe a trader might want to expose themselves to possible equity risk at a discount, and get paid to do it. Maybe. Keep in mind that Apple reports next week. That trader could...

- Sell one AAPL February 1st $150 put (Last: $2.20)

- Sell one JNJ April 18th $120 put (Last: $2.10)

Net Credit: $4.30... That's $430 up front.

Worst Case: Trader ends up long 100 shares of AAPL by next Friday at a net basis of $147.80. and long 100 shares of JNJ in April at a net basis of $117.90, with those stocks trading lower. Of course the trader would then sell calls against these positions at the time that the puts were exercised.

(Johnson & Johnson and Apple are holdings in Jim Cramer's Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells JNJ or AAPL? Learn more now.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stephen Guilfoye was Long AAPL equity. 

TAGS: Earnings | Investing | Markets | Options | Stocks | Trading | Healthcare | Pharmaceuticals | Software & Services | Stock of the Day

More from Investing

Emergent BioSolutions Turns Bearish, So Beware

Bruce Kamich
Mar 4, 2021 8:27 AM EST

A break in a key support level could precipitate further declines in the life sciences company's shares.

Steepening Yield Curve, All-Star Stocks Beatdown, Fed Speak, S&P Rally?

Stephen Guilfoyle
Mar 4, 2021 7:23 AM EST

Smaller to mid-cap names have fared somewhat better than large cap tech, but make no mistake... there is a circle of life/death here.

Jim Cramer: Playing the Relative Investing Game

Jim Cramer
Mar 4, 2021 6:41 AM EST

Investing can be fun until it turns brutal for what seems to be no reason.

Corrective Action Continues as Support Levels Fall

James "Rev Shark" DePorre
Mar 4, 2021 6:24 AM EST

Dip buyers have lost confidence as selling momentum builds.

With This Market, It's One Way, or the Other

Helene Meisler
Mar 4, 2021 6:00 AM EST

Let's look at this either/or market and why investors are complacent and ... getting angry.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 07:59 AM EST PAUL PRICE

    Fabulous news on United Natural Foods (UNFI)

    The major potential risk factor for UNFI, its cont...
  • 08:50 AM EST PAUL PRICE

    Michaels: Close to a Deal?

    It appears that a deal could be announced soon. ...
  • 08:34 AM EST GARY BERMAN

    Wednesday Morning Fibocall for 3/3/2021

    SPX (Long-Term View) The 20 DMA @ 3889 with the ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login